Entorhinal Cortex Layer II Neurons

Entorhinal Cortex Layer II Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Entorhinal Cortex Layer II Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Entorhinal Cortex Layer II Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Entorhinal Cortex Layer Ii Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Entorhinal Cortex Layer II Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Entorhinal Cortex Layer II Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Entorhinal Cortex Layer II Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Entorhinal Cortex Layer Ii Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The Entorhinal Cortex Layer II Neurons are a critical population of grid cells and intermediate neurons that form the primary gateway between the parahippocampal cortices and the hippocampus. These neurons are of paramount importance in neurodegenerative research because they represent the first site of neurofibrillary tangle formation in Alzheimer's disease (Braak Stage I), making them a key target for early detection and therapeutic intervention. [@moser2014]

Morphology and Markers

Cellular Morphology

• Cell types: Primarily stellate cells and fan cells (layer II projection neurons)
• Soma size: Medium to large pyramidal-shaped neurons (20-30 μm)
• Dendritic architecture: Vertically oriented apical dendrites extending to layer I
• Axonal projections: Strong projections to dentate gyrus granule cells (perforant path)
• Lamination: Distinct layer II positioned between layer I (molecular) and layer III (pre-α)

Molecular Markers

• Reelin (RELN): Strong expression in layer II stellate cells - key marker
• Calbindin D-28K (CALB1): Expressed in majority of layer II neurons
• Wnt2 (WNT2): Wingless signaling molecule, layer-specific expression
• RORB (ROR-beta): Nuclear receptor expressed in grid cells
• Calretinin (CALB2): Subpopulation marker
• CABP5: Calcium-binding protein specific to layer II

Grid Cell Properties

• Grid fields: Hexagonal spatial firing patterns (grid cells)
• Head direction integration: Combines with head direction signals
• Theta oscillations: Theta-nested firing (6-10 Hz)
• Speed modulation: Firing rate scales with running speed

Normal Function

Gateway to the Hippocampus

Perforant Path Circuitry

• Inputs: Perirhinal cortex, parahippocampal cortex, lateral entorhinal cortex
• Outputs:
• Lateral entorhinal cortex → dentate gyrus granule cells (perforant path)
• Medial entorhinal cortex → CA3 pyramidal neurons
• Synaptic targets: Dendritic spines on granule cells and CA3 neurons

Neurophysiological Properties

• Firing patterns: Grid cell spatial firing, theta-nested bursts
• Theta phase precession: Firing precedes hippocampal place cells
• Subthreshold oscillations: Depolarization at theta frequencies
• Integrative properties: Combines multiple sensory modalities

Vulnerability in Disease

Alzheimer's Disease - Earliest Site of Pathology

• Braak Stage I: Neurofibrillary tangles first appear in layer II neurons
• Selective vulnerability: Among the most vulnerable neurons in AD
• Pathology accumulation:
• Hyperphosphorylated tau in cell bodies and dendrites
• Early loss of Reelin-expressing neurons
• Amyloid deposition in outer molecular layer
• Mechanisms:
• Direct tau pathology propagation from entorhinal cortex
• Synaptic hyperactivity leading to excitotoxicity
• Impaired grid cell function before memory deficits
• Clinical correlation: Early grid cell dysfunction explains episodic memory loss

Other Neurodegenerative Diseases

• Lewy Body Disease: α-Synuclein pathology in entorhinal layer II
• Frontotemporal Dementia: Variable involvement depending on subtype
• Hippocampal Sclerosis: Often co-occurs with entorhinal pathology
• TGA (Transient Global Amnesia): Proposed entorhinal dysfunction

Therapeutic Implications

• Early detection: CSF and PET biomarkers targeting entorhinal pathology
• Tau-targeted therapies: Primary target for disease-modifying treatments
• Neuroprotective strategies: Support Reelin+ neuron survival
• Grid cell restoration: Novel therapeutic approach under investigation

Transcriptomic Profile

Key Differentially Expressed Genes

• RELN: Reelin - critical for layer-specific positioning
• RORB: ROR-beta - grid cell transcription factor
• CALB1: Calbindin - calcium buffering
• WNT2: Wingless protein - development and plasticity
• CPNE6 (CAP6): Neuronal calcium sensor
• NR2A (GRIN2A): NMDA receptor subunit
• GRIK1: Kainate receptor
• KCNA5: Potassium channel (theta modulation)

Disease-Associated Changes

• Tau phosphorylation genes: CDK5, GSK3B upregulation
• Synaptic proteins: PSD95, synaptophysin reduction
• Inflammatory markers: Increased GFAP, IBA1 in adjacent glia

Research Directions

Diagnostic Biomarkers

• CSF biomarkers: Neurofilament light chain (NfL), tau species
• Structural MRI: Entorhinal cortical thinning as early marker
• PET imaging: Tau PET shows early entorhinal uptake
• Functional MRI: Altered grid cell navigation paradigms

Therapeutic Targets

• Anti-tau antibodies: Designed to clear early entorhinal pathology
• Small molecule tau inhibitors: Target early phosphorylation
• Reelin enhancement: Support neuronal survival
• Neural stem cell therapy: Replace lost layer II neurons

Background

The study of Entorhinal Cortex Layer Ii Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@van2009]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@palop2016]

Additional evidence sources: [@tsao2013] [@berron2016] [@stranahan2012]

External Links

• [Allen Brain Atlas: Entorhinal Cortex](https://portal.brain-map.org/atlases-and-data/rnaseq)
• [Neurogrid: Grid Cell Activity](https://www.nature.com/neurosci/)
• [Human Brain Project: Entorhinal Circuitry](https://www.humanbrainproject.eu/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Perforant Path Presynaptic Terminal Protection Strategy](/hypothesis/h-76888762) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: PPARGC1A
• [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypothesis/h-e12109e3) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: MAP6
• [Reelin-Mediated Cytoskeletal Stabilization Protocol](/hypothesis/h-d2df6eaf) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: RELN
• [HCN1-Mediated Resonance Frequency Stabilization Therapy](/hypothesis/h-d40d2659) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: HCN1
• [Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics](/hypothesis/h-5ff6c5ca) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: SLC16A2
• [Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement](/hypothesis/h-57862f8a) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: IDH2
• [Mitochondrial Calcium Buffering Enhancement via MCU Modulation](/hypothesis/h-aa8b4952) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: MCU

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;